What is the Contineum Therapeutics, Inc. stock price forecast?

Contineum Therapeutics, Inc. is currently trading at $15.07. View real-time AI analysis on Alpha Lenz.

What is Contineum Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Contineum Therapeutics, Inc. on Alpha Lenz.

What is Contineum Therapeutics, Inc.'s P/E ratio?

Contineum Therapeutics, Inc.'s P/E ratio is -6.6.

Contineum Therapeutics, Inc.

NASDAQ · CTNM

$15.07+0.69(+4.83%)Live

Ask about Contineum Therapeutics, Inc.'s future dividend policy...

Alpha Chat Insight

“Contineum Therapeutics, Inc. trades at a P/E of -6.6 (undervalued) with modest ROE of -26.1%.”

Ask for details →

Company Overview

Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.

CEOMr. Carmine N. Stengone MBA, MS

Websitehttps://www.contineum-tx.com

SectorHealthcare

IndustryBiotechnology

Employees41

Company Statistics

FY 2025

Profile

$398.34MMarket Cap

$0.00Revenue

0.00Shares Out

41Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-6.64P/E

1.53P/B

N/AEV/Sales

-4.89EV/EBITDA

-7.17P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-24.51%ROA

-26.13%ROE

-27.81%ROIC

Financial Health

$75.60MCash & Cash Equivalents

$-59.95MNet Debt

6.00%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Contineum Therapeutics, Inc. trades at a P/E of -6.6 (undervalued) with modest ROE of -26.1%.”

Ask for details →

Frequently Asked Questions

Contineum Therapeutics, Inc. (ticker: CTNM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 41 employees. Market cap is $398M.

The current price is $15.075 with a P/E ratio of -6.64x and P/B of 1.53x.

ROE is -26.13%.